Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 214

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 ( SGLT2 ) inhibitor, as add‐on to metformin in type 2 diabetes with mild hyperglycaemia

Rosenstock, J., Seman, L. J., Jelaska, A., Hantel, S., Pinnetti, S., Hach, T., Woerle, H. J.·2013·Diabetes, Obesity and Metabolism

Abstract

Aims: To evaluate the effects of the sodium glucose cotransporter 2 ( SGLT2 ) inhibitor empagliflozin added to metformin for 12 weeks in patients with type 2 diabetes. Methods: This dose‐ranging, double‐blind, placebo‐controlled trial randomized 495 participants with type 2 diabetes inadequately controlled on metformin [haemoglobin A1c ( HbA1c ) >7 to ≤10%] to receive 1, 5, 10, 25, or 50 mg empagliflozin once daily ( QD ), or placebo, or open‐label sitagliptin (100 mg QD ), added to metformin for 12 weeks. The primary endpoint was change in HbA1c from baseline to week 12 (empagliflozin groups versus placebo). Results: Reductions in HbA1c of −0.09 to −0.56% were observed with empagliflozin after 12 weeks, versus an increase of 0.15% with placebo (baseline: 7.8–8.1%). Compared with placebo, empagliflozin doses from 5 to 50 mg resulted in reductions in fasting plasma glucose (−2 to −28 mg/ dl vs. 5 mg/ dl with placebo; p < 0.0001) and body weight (−2.3 to −2.9 kg vs. −1.2 kg; p < 0.01). Frequency of adverse events was generally similar with empagliflozin (29.6–48.6%), placebo (36.6%) and sitagliptin (35.2%). Hypoglycaemia rates were very low and balanced among groups. Most frequent adverse events with empagliflozin were urinary tract infections (4.0% vs. 2.8% with placebo) and pollakiuria (2.5% vs. 1.4% with placebo). Genital infections were reported only with empagliflozin (4.0%). Conclusions: Once daily empagliflozin as add‐on therapy to metformin was well tolerated except for increased genital infections and resulted in reductions in HbA1c , fasting plasma glucose and body weight in patients with type 2 diabetes inadequately controlled on metformin monotherapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/dom.12185

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 214

Metadata

Authors
Rosenstock, J., Seman, L. J., Jelaska, A., Hantel, S., Pinnetti, S., Hach, T., & Woerle, H. J.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2013-08-22
Volume
15
Issue
12
Pages
1154-1160
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W2165956693
Cited by
214
References
4
FWCI
23.35
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 ( SGLT2 ) inhibitor, as add‐on to metformin in type 2 diabetes with mild hyperglycaemia. https://app.cochat.ai/papers/10.1111/dom.12185
The paper
Rosenstock, J., Seman, L. J., Jelaska, A., Hantel, S., Pinnetti, S., Hach, T., & Woerle, H. J. (2013). Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 ( SGLT2 ) inhibitor, as add‐on to metformin in type 2 diabetes with mild hyperglycaemia. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.12185

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.